Randomized Controlled Trial of Paliperidone Extended Release Versus Risperidone for the Treatment of Methamphetamine-Associated Psychosis in Chinese Patients

Gang Wang, Fan Ding, Marek Cezary Chawarski, Wei Hao, Xuebing Liu, Qijian Deng, Xuan Ouyang, Gang Wang, Fan Ding, Marek Cezary Chawarski, Wei Hao, Xuebing Liu, Qijian Deng, Xuan Ouyang

Abstract

Background: The efficacy or tolerability of paliperidone extended release (ER) in the treatment of methamphetamine (METH)-associated psychosis (MAP) is unknown. This study was designed to assess the tolerability and efficacy of paliperidone ER and risperidone for the treatment of MAP in China.

Methods: This 25-day randomized clinical trial involved 120 patients with acute MAP symptoms who were randomized to receive either paliperidone ER or risperidone from baseline to day 25 of an inpatient hospital stay. The primary outcome was changes in the severity of psychosis, which were assessed using the Positive and Negative Syndrome Scale (PANSS) total score changes from baseline to endpoint.

Results: Overall, 84% of the patients completed the entire study protocol. The PANSS total score, the Clinical Global Impressions-Severity of Illness scale (CGI-S) score, and a METH craving score assessed by a visual analog scale (VAS) showed statistically significant improvements from baseline for the patients in both groups (p < 0.01). The Simpson-Angus Scale (SAS) and the Barnes Akathisia Rating Scale (BARS) scores increased from baseline during treatment in both groups (p < 0.01); there were statistically significant differences between the treatment groups in the SAS scores (p < 0.01). Measures of hypermyotonia, salivation, and dizziness were significantly higher in the risperidone-treated patients than in the paliperidone ER-treated patients (all p < 0.05).

Conclusion: Paliperidone ER and risperidone had similar efficacy and were generally tolerable in the treatment of MAP; however, paliperidone ER had a more favorable adverse event profile than risperidone, particularly regarding extrapyramidal and prolactin-increasing effects.

Clinical trial registration: ClinicalTrials.gov, identifier NCT01822730. Full date of first registration:03/28/2013.

Keywords: efficacy; methamphetamine; paliperidone extended-release; psychosis; risperidone; safety.

Copyright © 2020 Wang, Ding, Chawarski, Hao, Liu, Deng and Ouyang.

Figures

Figure 1
Figure 1
Screening, randomization, and follow-up of study participants.
Figure 2
Figure 2
Kaplan-Meier survival curves with proportion of patients remaining in treatment in the two study group.
Figure 3
Figure 3
Clinical adverse events reported by study participants treated with paliperidone and risperidone.

References

    1. United Nations Office of Drugs on Crime (UNODC) World Drug Report. Vienna, New York: United Nations Publications; (2018).
    1. Chinese National Narcotics Control Commission Annual Report on Drug Control in China (2010-2017) China.
    1. Whiteford HA, Degenhardt L, Rehm J, Baxter AJ, Ferrari AJ, Erskine HE, et al. Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study. Lancet (2013) 382(9904):1575–86. 10.1016/S0140-6736(13)61611-6
    1. Swanson SM, Sise CB, Sise MJ, Sack DI, Holbrook TL, Paci GM. The scourge of methamphetamine: impact on a level I trauma center. J Trauma (2007) 63(3):531–7. 10.1097/TA.0b013e318074d3ac
    1. McKetin R, McLaren J, Lubman DI, Hides L. Hostility among methamphetamine users experiencing psychotic symptoms. Am J Addict (2008) 17(3):235–40. 10.1080/10550490802019816
    1. Fusar-Poli P, Smieskova R, Serafini G, Politi P, Borgwardt S. Neuroanatomical markers of genetic liability to psychosis and first episode psychosis: a voxelwise meta-analytical comparison. World J Biol Psychiatry (2016) 15(3):219–28. 10.3109/15622975.2011.630408
    1. Serafini G, Pompili M, Haghighat R, Pucci D, Pastina M, Lester D, et al. Stigmatization of schizophrenia as perceived by nurses, medical doctors, medical students and patients. J Psychiatr Ment Health Nurs (2011) 18(7):576–85. 10.1111/j.1365-2850.2011.01706.x
    1. Glasner-Edwards S, Mooney LJ. Methamphetamine psychosis: epidemiology and management. CNS Drugs (2014) 28(12):1115–26. 10.1007/s40263-014-0209-8
    1. Sulaiman AH, Gill JS, Said MA, Zainal NZ, Hussein HM, Guan NC. A randomized, placebo-controlled trial of aripiprazole for the treatment of methamphetamine dependence and associated psychosis. Int J Psychiatry Clin Pract (2013) 17(2):131–8. 10.3109/13651501.2012.667116
    1. Farnia V, Shakeri J, Tatari F, Juibari TA, Yazdchi K, Bajoghli H, et al. Randomized controlled trial of aripiprazole versus risperidone for the treatment of amphetamine-induced psychosis. Am J Drug Alcohol Abuse (2014) 40(1):10–5. 10.3109/00952990.2013.861843
    1. Verachai V, Rukngan W, Chawanakrasaesin K, Nilaban S, Suwanmajo S, Thanateerabunjong R, et al. Treatment of methamphetamine-induced psychosis: a double-blind randomized controlled trial comparing haloperidol and quetiapine. Psychopharmacol (Berl) (2014) 231(16):3099–108. 10.1007/s00213-014-3485-6
    1. Wang G, Zhang Y, Zhang S, Chen H, Xu Z, Schottenfeld RS, et al. Aripiprazole and Risperidone for Treatment of Methamphetamine-Associated Psychosis in Chinese Patients. J Subst Abuse Treat (2016) 62:84–8. 10.1016/j.jsat.2015.11.009
    1. Chue PS, MacKenzie EM, Chue JA, Baker GB. The pharmacology and formulation of paliperidone extended release. Expert Rev Neurother (2012) 12(12):1399–410. 10.1586/ern.12.138
    1. Zhang L, Li J, Zhao Y, Su Y, Si T. Critical evaluation of paliperidone in the treatment of schizophrenia in Chinese patients: a systematic literature review. Neuropsychiatr Dis Treat (2016) 12:113–31. 10.2147/NDT.S64672
    1. Valsecchi P, Garozzo A, Nibbio G, Barlati S, Deste G, Turrina C, et al. Paliperidone extended-release in the short- and long-term treatment of schizophrenia. Riv Psichiatr (2019) 54(2):43–58. 10.1708/3142.31245
    1. Conley R, Gupta SK, Sathyan G. Clinical spectrum of the osmoticcontrolled release oral delivery system (OROS), an advanced oral delivery form. Curr Med Res Opin (2006) 22:1879–92. 10.1185/030079906X132613
    1. Wang SM, Han C, Lee SJ, Patkar AA, Pae CU, Fleischhacker WW. Paliperidone: a review of clinical trial data and clinical implications. Clin Drug Invest (2012) 32(8):497–512. 10.1007/BF03261901
    1. Seeman P. An update of fast-off dopamine D2 atypical antipsychotics. Am J Psychiatry (2005) 162:1984–85. 10.1176/appi.ajp.162.10.1984-a
    1. Schotte A, Janssen PF, Gommeren W, Luyten WH, Van Gompel P, Lesage AS, et al. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (1996) 124:57–73. 10.1007/BF02245606
    1. Richelson E, Souder T. Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci (2000) 68(1):29–39. 10.1016/S0024-3205(00)00911-5
    1. Cai S, Lu H, Bai Z, Wu R, Zhao J. Paliperidone extended-release tablets in Chinese patients with schizophrenia: meta-analysis of randomized controlled trials. Neuropsychiatr Dis Treat (2015) 11:1817–34. 10.2147/NDT.S84833
    1. Yoon KS, Park TW, Yang JC, Kim MG, Oh KY, Park MS, et al. Different safety profiles of risperidone and paliperidone extended-release: a double-blind, placebo-controlled trial with healthy volunteers. Hum Psychopharmacol (2012) 27(3):305–14. 10.1002/hup.2227
    1. Kim SW, Chung YC, Lee YH, Lee JH, Kim SY, Bae KY, et al. Paliperidone ER versus risperidone for neurocognitive function in patients with schizophrenia: a randomized, open-label, controlled trial. Int Clin Psychopharmacol (2012) 27(5):267–74. 10.1097/YIC.0b013e328356acad
    1. Machin D, Michael JC, Peter M, Fayers, Alain PYP. (1997). Sample Size Tables for Clinical Studies, 2nd Edition, Oxford.
    1. Malden MA, Zar JH. Biostatistical Analysis (Second Edition). New Jersey: Prentice-Hall, Englewood Cliffs; (1984).
    1. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull (1987) 13:261–76. 10.1093/schbul/13.2.261
    1. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry (1989) 154:672–76. 10.1192/bjp.154.5.672
    1. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl (1970) 212:11–9. 10.1111/j.1600-0447.1970.tb02066.x
    1. Gueorguieva R, Krystal JH. Move over ANOVA: progress in analyzing repeated-measures data and its reflection in papers published in the Archives of General Psychiatry. Arch Gen Psychiatry (2004) 61(3):310–17. 10.1001/archpsyc.61.3.310
    1. Cookson J, Hodgson R, Wildgust HJ. Prolactin, hyperprolactinema and antipsychotic treatment: a review and lessons for treatment of early psychosis. J Psychopharmacol (2012) 26:42–51. 10.1177/0269881112442016
    1. Rounsaville BJ. DSM-V Research Agenda: Substance Abuse/Psychosis Comorbidity. Schizophr Bull (2007) 33:947–52. 10.1093/schbul/sbm054
    1. Wang G, Ma L, Liu X, Yang X, Zhang S, Yang Y, et al. Paliperidone Extended-Release Tablets for the Treatment of Methamphetamine Use Disorder in Chinese Patients After Acute Treatment: A Randomized, Double-Blind, Placebo-Controlled Exploratory Study. Front Psychiatry (2019) 10:656. 10.3389/fpsyt.2019.00656
    1. Chen CK, Lin SK, Chen YC, Huang MC, Chen TT, Ree SC, et al. Persistence of psychotic symptoms as an indicator of cognitive impairment in methamphetamine users. Drug Alcohol Depend (2015) 148:158–64. 10.1016/j.drugalcdep.2014.12.035

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다